Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer [0.03%]
细胞周期穿越率可预测三阴性乳腺癌患者的长期预后：一项多机构队列研究
Shristi Bhattarai,Manali Rupji,Hsueh-Ping Chao et al.
Shristi Bhattarai et al.
Background: Ki67 index (KI) and mitotic index (MI) are proliferation markers with established prognostic value in breast carcinomas. While KI is evaluated immunohistochemically and reported as a percentage, MI is determin...
Systematic review of risk prediction tools for primary cutaneous melanoma outcomes and validation of sentinel lymph node positivity prediction in a UK tertiary cohort [0.03%]
英国三级医疗中心黑色素瘤患者淋巴结阳性预测系统的系统评价及验证研究
R N Manton,A Roshan
R N Manton
Background: It is difficult for clinicians to make predictions for cancer progression or outcomes based on AJCC staging for individual patients. Models individualising risk prediction for clinical outcomes are developed u...
Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis [0.03%]
靶向TROP-2的抗体药物偶联物sacituzumab govitecan治疗实体瘤的有效性和安全性及UGT1A1*28多态性：系统评价和荟萃分析
Rehena Sultana,Sylvia Chen,Elaine Hsuen Lim et al.
Rehena Sultana et al.
Background: Sacituzumab govitecan (SG) is a promising Trop-2-targeted antibody-drug conjugate (ADC) approved for the treatment of metastatic triple-negative breast cancer (TNBC). Early phase clinical trials have demonstra...
Commentary: Why is genetic testing underutilized worldwide? The case for hereditary breast cancer [0.03%]
全球基因检测为何利用率偏低？以遗传性乳腺癌为例分析原因
Holly J Pederson,Steven A Narod
Holly J Pederson
It is thirty years since the BRCA1 and BRCA2 genes were discovered and genetic testing for BRCA1 and BRCA2 was introduced. Despite increasing awareness of the genetic basis of cancer and our evolving knowledge of effective means of preventi...
Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors [0.03%]
免疫检查点抑制剂治疗患者的绝对淋巴细胞计数的预后影响研究
M R Conroy,H O&#x;Sullivan,D C Collins et al.
M R Conroy et al.
Background: The role of immune checkpoint inhibitors (ICI) expands but affordable and reproducible prognostic biomarkers are needed. We investigated the association between baseline and 3-month absolute lymphocyte count (...
The impact of elective cervical lymph node treatment on the tumour immune response in head and neck squamous cell carcinoma: time for a change in treatment strategy? [0.03%]
选择性颈淋巴结治疗对头颈部鳞状细胞癌肿瘤免疫反应的影响：是时候改变治疗策略了吗？
Karl Payne,Pablo Nenclares,Clare Schilling
Karl Payne
The elective ablation of cervical lymph nodes, via surgery or irradiation, is a mainstay in the treatment of head and neck squamous cell carcinoma (HNSCC). In this setting, the decision to treat the clinically node negative neck is based up...
What's in a name? Refining the nomenclature of liver metastases growth patterns by changing "desmoplastic" to "encapsulated" [0.03%]
什么是名称？通过将“粘膜”改为“囊封”，完善肝转移瘤生长模式的命名法
Carlos Fernández Moro,Béla Bozóky,Natalie Geyer et al.
Carlos Fernández Moro et al.
Best analgesia control in pancreatic adenocarcinoma study: justification and feasibility of a randomised trial of early EUS-CPN versus standard care-a prospective observational study (The BAC-PAC study) [0.03%]
胰腺导管腺癌镇痛控制最佳方法的研究：一项关于内镜超声引导下的腹腔神经丛阻滞与标准治疗的随机对照试验的合理性及可行性研究（BAC-PAC研究）
Andreas I Koulouris,Adam P Wagner,Allan Clark et al.
Andreas I Koulouris et al.
Introduction: Limited and conflicting trial data is available on the efficacy of Endoscopic Ultrasound-guided Coeliac Plexus Neurolysis (EUS-CPN). This study aimed to assess the feasibility, justification and to inform de...
A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer [0.03%]
一项关于纳武单抗与改良FOLFIRINOX联合治疗转移性胰腺癌的II期研究
Chigusa Morizane,Makoto Ueno,Masafumi Ikeda et al.
Chigusa Morizane et al.
Background: Nivolumab with modified FOLFIRINOX (mFOLFIRINOX) may have additive antitumour effects while minimising chemotherapy cytotoxicity. We assessed the efficacy and safety of nivolumab+mFOLFIRINOX in metastatic panc...
Penetrance estimates of hereditary cancers in a population setting using UK Biobank data [0.03%]
英国生物样本库数据在人群设置中估计遗传癌症的外显率
Ranjit Manchanda,D Gareth Evans,Antonis C Antoniou et al.
Ranjit Manchanda et al.